MS-Hu6

MS-Hu6 is a first-in-class, humanized monoclonal antibody targeting follicle-stimulating hormone beta subunit (FSHβ). It was derived by humanization of the murine Hf2 antibody and designed to bind specifically to a 13-amino acid epitope within the receptor-binding sequence of FSHβ, thereby blocking its interaction with the follicle-stimulating hormone receptor (FSHR). This antagonism results in inhibition of FSH signaling, which in preclinical models has led to reduced body fat, increased thermogenic adipose tissue, improved bone density, and prevention of neurodegeneration[10][8][5]. MS-Hu6 has shown high affinity for FSHβ (Kd ~7.5 nM), and is non-immunogenic based on in vitro assays[10][5]. Its intended clinical development includes indications such as obesity, osteoporosis, and potentially Alzheimer’s disease[10][5]. Unlike other metabolic therapies, it exerts effects through direct hormonal blockade, offering a unique therapeutic avenue among metabolic and aging-related disorders.